Professor Karen Sliwa to lead a global prospective cohort study which aims to better describe cardiovascular outcomes and identify cardiovascular risk factors associated with poor prognosis in patients with COVID-19.

29 Apr 2020 - 07:15

The World Heart Federation (WHF) is committed to supporting the fight against the COVID-19 pandemic. In order to better understand the intersection between cardiovascular disease and COVID-19, WHF will embark on a global prospective cohort study which aims to better describe cardiovascular outcomes and identify cardiovascular risk factors associated with poor prognosis in patients with COVID-19.

The study is supported by the WHF Science Committee and led by:

Professor Karen Sliwa, WHF President, Director, Hatter Institute for Cardiovascular Research University of Cape Town, South Africa.

Professor Dorairaj Prabhakaran, WHF Science Committee Chair, Vice President (Research and Policy) and Director, Centre for Control of Chronic Conditions, Public Health Foundation India.

Professor Pablo Perel, WHF Senior Science Advisor, London School of Hygiene and Tropical Medicine, UK.

Co-investigators are WHF President-Elect Prof Fausto Pinto, Prof Friedrich Thienemann, Prof Junbo Ge, Prof Carolyn Lam, Dr Dike Ojji, Dr Amitava Banerjee, Prof Kristin Newby, Dr Samuel Gidding, Dr Antonio Robeiro and Dr Kavita Singh.

All WHF Members are invited to identify and endorse at least two hospitals or other medical facilities (recruiting centres) in their respective countries. Each centre should recruit between 50 and 200 COVID-19 patients. There is no limit in the number of sites that can take part. The study, due to start in May 2020, will include all adults (as locally defined) with confirmed COVID-19 infection who are hospitalized. 

Data will be collected from the patient’s routine medical records and no special tests will be required. Local investigators will use a secure electronic form to submit the data to the coordinating centre, which will take 15-20 minutes for each patient. Data will be collected at baseline and discharge. Follow-up will take place after 30 days. If a patient is discharged before the follow-up is conducted, a phone call will be made to determine patient outcome.

This is a non-commercial study and as such we can provide USD 25 per completed case report to cover the time to complete the forms. WHF Members and site investigators participating in the study will be actively involved in the study publications.

This global pandemic requires a global understanding and response and we are very proud to work together with you, our Members, on this important study.

If you would like to register your interest, please correspond directly to: Lana Raspail, Programme Officer, lana.raspail@worldheart.org.

TOP